the-clinical-benefits-of-monoclonal-antibodies 
Electronic Health Reporter
DECEMBER 13, 2021
Monoclonal antibodies are synthetic proteins developed for therapeutic use in patients with a range of serious conditions, including Ebola, cancer, and COVID-19. Monoclonal antibodies are produced in a laboratory setting like any other therapeutic approach […]. Illegal copying is prohibited.
Bill of Health
JANUARY 31, 2022
Over the past few months, we have seen the arrival and wider availability of treatments such as monoclonal antibodies (mAbs), and more recently, of novel oral antiviral drugs like Paxlovid and molnupiravir. In an open-access Viewpoint in Clinical Infectious Diseases , we identify ethical goals for the allocation of scarce therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Law Advisor
JANUARY 13, 2022
If the proposal is adopted by CMS, it would set in motion a detailed regulatory process that includes temporary Medicare coverage for the drug but only for certain Medicare beneficiaries who are enrolled in an additional clinical trial intended to test whether these drugs will have a significant benefit for Medicare beneficiaries.
HIT Consultant
MARCH 7, 2022
Earlier last year, the FDA issued an emergency use authorization (EUA) for monoclonal antibody treatments bringing additional needs for infusion treatments in many alternate care settings. Roger Massengale, Chief Commercial Officer, Eitan Medical. Initially, infusion pumps were requested for Covid patients connected to ventilators.
Healthcare IT News - Telehealth
MAY 7, 2021
"At Sanford Health, the largest rural health system in the country, our leaders have always recognized the importance and the power of data, but the COVID-19 pandemic revealed the meaningful benefits of investing in the resources and infrastructure needed for a strong data analytics department," she said.
Exeed Regulatory Compliance
OCTOBER 19, 2020
A “cocktail” of two potent monoclonal antibodies from Regeneron could be a breakthrough early intervention for COVID-19. We want to learn as much as we can from publicly available technical information, understand the evolving benefit-risk and be aware of our available options.
Bill of Health
OCTOBER 24, 2022
with no phase IV clinical trials); Registered products for off label use (e.g., products under conditional marketing authorization or approved for Emergency Use Listing, such as monoclonal antibodies). with no phase IV clinical trials); Registered products for off label use (e.g.,
Expert insights. Personalized for you.
79 
Let's personalize your content